PREMARINE 0.625mg Price

Overview

Welcome to Dwaey, specifically on PREMARINE 0.625mg Tablets page.
This medicine contains an important and useful components, as it consists of Oestrogens (conjugated).
PREMARINE 0.625mg is available in the market in concentration 0.625mg/Tablet and in the form of Tablets.

WYETH CANADA is the producer of PREMARINE 0.625mg and it is imported from CANADA, The most popular alternatives of PREMARINE 0.625mg are listed downward .

Mode Of Action

Estrogens modulate pituitary secretion of gonadotropins, leutinising hormones and follicle-stimulating hormones through -ve feedback mechanism, thus reducing elevated levels of hormones in postmenopausal women during oestrogen replacement therapy.

Indication

• Osteoporosis
• Fungal infections
• Itching
• Burning
• Hot flashes
• Vaginal dryness
• Vaginal atrophy
• Menopausal symptoms
• Female hypogonadism
• Metastatic breast carcinoma
• Ovarian failure
• Prostate carcinoma
• Primary ovarian failure
• Hormone replacement therapy
• Oral contraceptives

Precaution

Asthma, epilepsy, migraine; heart or kidney dysfunction; CV disease; cerebrovascular disorders; diabetes, hypercalcaemia; gall bladder disease; porphyria. Childn. Lactation. Lactation: Use controversial; estrogens are excreted into breast milk in small quantities; use with caution

Side Effects

• >10% Abdominal pain (15-17%)
• Back pain (13-14%)
• Breast enlargement
• Breast tenderness (7-12%)
• Headache (26-32%)
• Arthralgia (7-14%)
• Pharyngitis (10-12%)
• Sinusitis (6-11%)
• Diarrhea (6-7%) 1-10% Depression (5-8%)
• Dizziness (4-6%)
• Nervousness (2-5%)
• Flatulence (6-7%)
• Vaginitis (5-7%)
• Leukorrhea (4-7%)
• Leg cramps (3-7%)
• Increased cough (4-7%)
• Pruritus (4-5%) Frequency Not Defined Amenorrhea
• Breakthrough bleeding
• Corneal curvation change
• Melasma
• Spotting
• Vaginal moniliasis
• Weight changes Potentially Fatal: Unopposed replacement therapy in postmenopausal women associated with increased risk of endometrial and breast cancer. Potentially Fatal: Unopposed replacement therapy in postmenopausal women associated with increased risk of endometrial and breast cancer.

Contra indication

Severe liver impairment; breast carcinoma; thromboembolic disorders; CV disease; undiagnosed vag bleeding; estrogen-dependent neoplasms; hypersensitivity; pregnancy.

Pregnancy and lactation

Pregnancy category: X

Studies in animals or humans have demonstrated fetal abnormalities and/or there is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience, and the risks involved in use of the drug in pregnant women clearly outweigh potential benefits.